How long does stem cell therapy for Scleroderma (Systemic Sclerosis) last?
Durability differs by intervention and cannot be summarised across HSCT and MSC products. Long-term follow-up after HSCT includes relapse, organ outcomes and late treatment complications; durable benefit from placental MSC infusion is not established. Neither approach should be described as a cure, and no standard MSC retreatment interval is established.
How stem cells are studied for Scleroderma (Systemic Sclerosis)
Systemic sclerosis (scleroderma) is an autoimmune disease involving fibrosis and vascular and immune dysfunction that may affect skin and internal organs. Two very different approaches must not be conflated. Autologous haematopoietic stem-cell transplantation (HSCT) is an intensive specialist treatment considered in selected people with severe, early diffuse cutaneous systemic sclerosis after careful cardiopulmonary risk assessment. Placental or other mesenchymal stromal cell (MSC) products remain investigational and have not established the same clinical role. The registry table on this page lists relevant studies and their current recruitment status.
Am I a candidate? → · Scleroderma (Systemic Sclerosis): full overview → · Scleroderma (Systemic Sclerosis) cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Scleroderma (Systemic Sclerosis): cell-therapy evidence and registered trials
- How much does stem cell therapy for Scleroderma (Systemic Sclerosis) cost? (2026)
- Scleroderma (Systemic Sclerosis) stem cell therapy — your questions answered (2026)
- Scleroderma (Systemic Sclerosis): cell-therapy evidence by therapy class
- MSC vs HSCT for Scleroderma (Systemic Sclerosis): what the registries show